Suriname
Tuberculosis profile
| High HIV burden |
Population  2013 <1 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.012 (0.011–0.013) 2.2 (2.1–2.4)
Mortality (HIV+TB only) 0.012 (<0.01–0.016) 2.2 (1.6–2.9)
Prevalence  (includes HIV+TB) 0.27 (0.14–0.44) 50 (26–81)
Incidence  (includes HIV+TB) 0.21 (0.18–0.26) 39 (33–48)
Incidence (HIV+TB only) 0.048 (0.041–0.06) 9 (7.5–11)
Case detection, all forms (%) 67 (54–80)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 2.2 (1.3–3.1) 14 (4.7–22)
MDR-TB cases among notified pulmonary
TB cases
3 (2–4) 1 (0–2)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 108   2
Pulmonary, clinically diagnosed 18   0
Extrapulmonary 11   2
       
Total new and relapse 141    
Previously treated, excluding relapses 5    
Total cases notified 146    
Among 141 new and relapse cases:
12 (9%) cases aged under 15 years; male:female ratio: 2.9
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 76 (70%) 2 (22%) 78
Laboratory-confirmed RR-/MDR-TB cases     4
Patients started on MDR-TB treatment     0
TB/HIV 2013 Number (%)
TB patients with known HIV status 135 (92)
HIV-positive TB patients 31 (23)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 1 (3)
HIV-positive TB patients on antiretroviral therapy (ART) 14 (45)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New cases registered in 2012 66
Previously treated cases registered in 2012 75
HIV-positive TB cases, all types, registered in 2012 56
RR-/MDR-TB cases started on second-line treatment in 2011  
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 0.6
Culture (per 5 million population) 9.3
Drug susceptibility testing (per 5 million population) 0
Sites performing Xpert MTB/RIF 2
Is second-line drug susceptibility testing available? No
Financing TB control 2014  
National TB programme budget (US$ millions)  
% Funded domestically  
% Funded internationally  
% Unfunded  
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-07-02 Data: www.who.int/tb/data